Disease · MONDO_0019933
acromegaly
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. acromegaly. Diseases, record MONDO_0019933. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019933
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Highest stage of its drugs
- Approval, for 8 of its 25 drugs, from ClinicalTrials.gov, DailyMed, EMA Human Drugs, FDA, PMDA and TTD
- Open Targets
Drugs25
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| OCTREOTIDE | CHEMBL1680 | Protein | Approval | EMA Human Drugs and TTD | 34 | 31 | 31 | Drugs and targets |
| PEGVISOMANT | CHEMBL1201515 | Protein | Approval | DailyMed, EMA Human Drugs, PMDA and TTD | 20 | 15 | 15 | Drugs and targets |
| OCTREOTIDE ACETATE | CHEMBL1200480 | Protein | Approval | DailyMed and PMDA | 18 | 10 | 10 | Drugs and targets |
| PASIREOTIDE | CHEMBL3349607 | Protein | Approval | ClinicalTrials.gov and EMA Human Drugs | 10 | 9 | 9 | Drugs and targets |
| PALTUSOTINE | CHEMBL5267842 | Small molecule | Approval | EMA Human Drugs | 8 | 5 | 5 | Drugs and targets |
| LANREOTIDE ACETATE | CHEMBL1201184 | Protein | Approval | DailyMed, PMDA and TTD | 6 | 2 | 2 | Drugs and targets |
| BROMOCRIPTINE MESYLATE | CHEMBL1200503 | Small molecule | Approval | DailyMed and FDA | 3 | 0 | 0 | Drugs and targets |
| PASIREOTIDE PAMOATE | CHEMBL5314382 | Protein | Approval | DailyMed and PMDA | 2 | 0 | 0 | Drugs and targets |
| LANREOTIDE | CHEMBL1201185 | Protein | Phase 3 | ClinicalTrials.gov | 15 | 15 | 15 | Drugs and targets |
| CABERGOLINE | CHEMBL1201087 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
1 to 10 of 25
See all 25 drugsTargets14
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| SSTR2 | Somatostatin receptor | 10 | Somatostatin receptor 2 agonist; Somatostatin receptor agonist | Approval | https://conductscience.org/library/genes/6752 | Drugs and targets |
| SSTR5 | Somatostatin receptor | 9 | Somatostatin receptor 5 agonist; Somatostatin receptor agonist | Approval | https://conductscience.org/library/genes/6755 | Drugs and targets |
| SSTR1 | Somatostatin receptor | 5 | Somatostatin receptor 1 agonist; Somatostatin receptor agonist | Approval | https://conductscience.org/library/genes/6751 | Drugs and targets |
| SSTR3 | Somatostatin receptor | 5 | Somatostatin receptor 3 agonist; Somatostatin receptor agonist | Approval | https://conductscience.org/library/genes/6753 | Drugs and targets |
| SSTR4 | Somatostatin receptor | 4 | Somatostatin receptor 4 agonist; Somatostatin receptor agonist | Approval | https://conductscience.org/library/genes/6754 | Drugs and targets |
| DRD2 | D(2) dopamine receptor | 3 | D2-like dopamine receptor agonist; Dopamine D2 receptor agonist | Approval | https://conductscience.org/library/genes/1813 | Drugs and targets |
| ESR1 | Estrogen receptor | 2 | Estrogen receptor alpha agonist; Estrogen receptor alpha modulator | Phase 2 | https://conductscience.org/library/genes/2099 | Drugs and targets |
| GHR | Growth hormone receptor | 2 | Growth hormone receptor agonist; Growth hormone receptor antagonist | Approval | https://conductscience.org/library/genes/2690 | Drugs and targets |
| DRD3 | D2-like dopamine receptor | 1 | D2-like dopamine receptor agonist | Approval | https://conductscience.org/library/genes/1814 | Drugs and targets |
| DRD4 | D2-like dopamine receptor | 1 | D2-like dopamine receptor agonist | Approval | https://conductscience.org/library/genes/1815 | Drugs and targets |
1 to 10 of 14
See all 14 targetsTrials84
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00600886 | Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly | Phase 3 | 358 | 2015-01-30 | Acromegaly | OCTREOTIDE, PASIREOTIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01137682 | Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly | Phase 3 | 198 | 2015-01-21 | Acromegaly | PASIREOTIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01412424 | Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly | Phase 3 | 155 | 2015-12-01 | Acromegaly | OCTREOTIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02685709 | Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly | Phase 3 | 146 | 2022-04-22 | Acromegaly | CABERGOLINE, OCTREOTIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02493517 | Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly | Phase 3 | 128 | 2018-12-14 | Acromegaly | LANREOTIDE, LANREOTIDE ACETATE | Its record names the disease | ClinicalTrials.gov |
| NCT00383708 | Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients | Phase 3 | 125 | 2018-07-23 | Acromegaly | LANREOTIDE, PEGVISOMANT | Its record names the disease | ClinicalTrials.gov |
| NCT02354508 | Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues | Phase 3 | 123 | 2019-12-04 | Acromegaly | PASIREOTIDE | Its record names the disease | ClinicalTrials.gov |
| NCT05192382 | A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2) | Phase 3 | 111 | 2026-01-13 | Acromegaly | PALTUSOTINE | Its record names the disease | ClinicalTrials.gov |
| NCT00994214 | Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly | Phase 2 | 109 | 2016-02-10 | Acromegaly | ONZIGOLIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00690898 | Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma | Phase 3 | 108 | 2013-12-23 | Acromegaly | LANREOTIDE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 84
See all 84 trialsComparisons in its trials26
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Up-titrated to Pasireotide LAR 60 mg vs Pasireotide LAR Overall: deaths from any cause | 0 of 92 | 0 of 123 | 215 | NCT02354508 | Trial comparisons |
| Up-titrated to Pasireotide LAR 60 mg vs Pasireotide LAR Overall: serious adverse events | 6 of 92 | 12 of 123 | 215 | NCT02354508 | Trial comparisons |
| Lanreotide Autogel vs Lanreotide PR: deaths from any cause | 0 of 64 | 0 of 64 | 128 | NCT02493517 | Trial comparisons |
| Lanreotide Autogel vs Lanreotide PR: serious adverse events | 1 of 64 | 2 of 64 | 128 | NCT02493517 | Trial comparisons |
| Run-in Period vs Co-administration Period: deaths from any cause | 0 of 57 | 0 of 57 | 114 | NCT00383708 | Trial comparisons |
| Run-in Period vs Co-administration Period: serious adverse events | 2 of 57 | 8 of 57 | 114 | NCT00383708 | Trial comparisons |
| RCT Phase - Oral vs RCT Phase - Injectables: Proportion of Patients With Clinical and Biochemical Control at the End of the RCT Phase | 36 of 55 | 27 of 37 | 92 | NCT02685709 | Trial comparisons |
| RCT Phase - Oral vs RCT Phase - Injectables: Proportion of Patients Who Are Biochemically Controlled Throughout the RCT Phase | 50 of 55 | 37 of 37 | 92 | NCT02685709 | Trial comparisons |
| RCT Phase - Oral vs RCT Phase - Injectables: Proportion of Patients on Octreotide Capsules Who Are Biochemically Controlled at the End of the RCT Phase- Landmark Analysis | 49 of 55 | 35 of 37 | 92 | NCT02685709 | Trial comparisons |
| RCT Phase - Oral vs RCT Phase - Injectables: Proportion of Patients Who Maintain or Reduce the Overall Number of Active Acromegaly Symptoms at the End of the RCT Phase | 41 of 55 | 26 of 37 | 92 | NCT02685709 | Trial comparisons |
1 to 10 of 26
See all 26 comparisons in its trialsPapers from its trials88
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019933
GET https://conductscience.org/api/diseases/v1/MONDO_0019933/drugs?page=2